Neuraminidase immunotherapy: serum potentiation of lymphocyte cytotoxicity related to immunoglobulin levels.
Seven patients completed couses of immunotherapy using neuraminidase-altered autochthonous cells. Their response to therapy was monitored by a cytotoxicity assay using 3H-proline-tagged tumor cells from the patient's own cultured tumor in a strictly autologous system. Serum effects were measured by exposing the tumor target cells to serum to see whether this impeded (blocked) or augmented (potentiated) lymphocyte cytotoxicity. Three of the seven patients developed increasing degrees of serum blocking effect and all died within six months of completing therapy. Four of the seven showed rapidly decreasing blocking and three eventual potentiation. Three patients are living, improved, and free of evidence of tumor. There was an increase in average serum immunoglobulins in patients developing potentiation, and a decrease in those showing blocking. In any immunotherapy program attention must be given to in vitro monitoring studies, and such studies should include attention to the serum factors influencing host response.
D000328:Adult; D000368:Aged; D000951:Antigens, Neoplasm; D003601:Cytotoxicity Tests, Immunologic; D005260:Female; D006801:Humans; D007136:Immunoglobulins / Q000032:analysis; D007167:Immunotherapy; D008214:Lymphocytes / Q000276:immunology*; D008875:Middle Aged; D009369:Neoplasms / Q000097:blood / Q000276:immunology / Q000628:therapy*; D009439:Neuraminidase / Q000494:pharmacology*
D000951:Antigens, Neoplasm; D007136:Immunoglobulins; D009439:Neuraminidase